Sign up to save your podcasts
Or
Share Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors
Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL? Credit available for this activity expires: 12/05/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.3
2323 ratings
Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL? Credit available for this activity expires: 12/05/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
The Bob Harrington Show
13 Listeners
NEJM This Week
315 Listeners
Diabetes Core Update
107 Listeners
JACC This Week
172 Listeners
This Week in Cardiology
865 Listeners
JAMA Clinical Reviews
495 Listeners
AFP: American Family Physician Podcast
686 Listeners
One-on-One with Eric Topol
18 Listeners
Mayo Clinic Talks
279 Listeners
Frankly Speaking About Family Medicine
254 Listeners
The Curbsiders Internal Medicine Podcast
3,321 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
137 Listeners
Core IM | Internal Medicine Podcast
1,108 Listeners
The Peter Attia Drive
7,983 Listeners
Annals On Call Podcast
195 Listeners
Medicine and the Machine
60 Listeners
Keeping Current
8 Listeners
Cardionerds: A Cardiology Podcast
426 Listeners
The Cribsiders
314 Listeners